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Introduction
Phosphoinositide 3-kinase (PI3K) was first detected in
the 1980s as a novel lipid kinase activity found associ-
ated with several oncogene products (v-Ros, v-Src and
polyoma virus middle T antigen [mT]) and subsequently
with many activated growth factor receptor complexes
[1]. It is surprising, given this beginning, that it was not
until the late 1990s that a PI3K was isolated, first as a
retroviral oncogene and then implicated in several human
cancers [2]. It is now clear that alterations in PI3K sig-
nalling cassettes can lead to changes in a number of cell
functions that contribute to the transformed phenotype,
including cell growth and proliferation, differentiation, cell
survival, adhesion and cell motility [2,3]. The PI3K family
of enzymes, their targets, and regulators are thus now
considered important potential therapeutic targets [4]. In
this review, the PI3K superfamily will be briefly described
with respect to how these enzymes function and are reg-
ulated. The emerging data implicating PI3K signalling in
human cancer, with special reference to possible roles in
breast disease, will be considered.
The PI3K superfamily
The PI3K superfamily is defined by sequence motifs
present in the catalytic domain of these enzymes [1,5].
There are at least 12 members of this family present in the
human genome that can be divided into two main groups.
The true PI3Ks display lipid kinase and some protein
kinase activity, and are further subdivided into Class I–III
enzymes. The PI3K-related enzymes (Class IV) are large
proteins that possess protein kinase activity only [6].
Class I PI3Ks
Class I PI3Ks have been studied most extensively and are
best understood. It was a Class I PI3K that was originally
found associated with oncogene products, and a member
of this family was the first to be cloned [1]. Class I PI3Ks
are activated by diverse cell surface receptors including
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G-protein-coupled receptors, by receptors with either
intrinsic or associated protein-tyrosine kinase (PTK) activ-
ity, by association with tyrosine phosphorylated proteins
(e.g. insulin-regulated substrate 1) and, in addition, by the
action of small G proteins (e.g. Ras) [1]. Class I PI3Ks can
phosphorylate phosphatidylinositol (PtdIns), PtdIns4P and
PtdIns(4,5)P2 in vitro to generate PtdIns3P, PtdIns(3,4)P2
and PtdIns(3,4,5)P3, respectively. PtdIns(4,5)P2, on acti-
vation in vivo, is believed to be the preferred substrate.
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are found at low levels
in resting cells and increase dramatically on stimulation
[1]. Class I PI3Ks also possess some protein kinase activ-
ity towards specific substrates, but the significance of this
remains controversial [1,5]. Class I is subdivided into
Class IA and Class IB.
Class IA PI3Ks are heterodimeric, consisting of a 110 kDa
catalytic subunit and a 55–85 kDa regulatory subunit [1,5].
There are three Class IA catalytic subunits in the human
genome: p110α, p110β and p110δ (Fig. 1). There are also
three regulatory subunits (p85α, p85β and p55PIK),
although additional forms exist owing to alternative splicing.
All of the regulatory subunits contain two Src homology 2
domains flanking a p110-binding site. The p85 isoforms
also possess an N-terminal Src homology 3 domain. These
Src homology 2 and Src homology 3 domains mediate the
recruitment and regulation of Class IA PI3Ks by a multitude
of activated PTKs, with the PI3K usually being recruited
either directly to the receptor via binding to autophosphory-
lations sites or via substrate proteins such as insulin-regu-
lated substrate 1 [1].
A single Class IB heterodimeric enzyme exists, consisting of
the 110 kDa catalytic subunit, p110γ, and a 101 kDa regu-
latory subunit. Unlike the p85 subunits, p101 contains no
obvious signalling modules or motifs. The Class IB enzyme
is subject to regulation by G-protein signalling and thus is
linked to activation by G-protein-coupled receptors [1,5].
Class II PI3Ks
The Class II PI3Ks are structurally related to the Class I
enzymes, but lack the p85/p101 binding motifs and
instead possess additional regulatory domains including
the phox homology and C2 domains (Fig. 1) [5]. Class II
PI3Ks can utilise PtdIns and PtdIns4P, but not
PtdIns(4,5)P2 in vitro. Like Class I enzymes, Class II PI3Ks
are linked to diverse receptor-mediated signalling
processes, including integrin signalling in platelets,
chemokine signalling, insulin, and epidermal growth factor
(EGF) and platelet-derived growth factor signalling (see
[7] and references therein). There are three human Class II
PI3Ks: PI3KC2α and PI3KC2β are widely expressed in
mammalian tissues [8,9], and PI3K-C2γ is restricted to a
few tissues including the liver, breast and prostate
[10,11]. The function(s) and in vivo substrates of the
Class II PI3Ks remain to be determined.
Class III PI3Ks
Class III PI3Ks are PtdIns-specific enzymes generating only
PtdIns3P in vitro or in vivo, the prototype being the Sac-
charomyces cerevisiae protein Vps34p (the only PI3K
present in this yeast genome), which is involved in vesicle
sorting and trafficking [5,12]. A single mammalian homo-
logue has been identified and is suggested to play a similar
role in intracellular trafficking processes. The human and
yeast Vps34 proteins both associate with an N-terminally
myristoylated serine/threonine kinase (Vps15/p150), which
recruits Vps34 to cell membranes and enhances its lipid
kinase activity [5,12]. While this Class of PI3K is not nor-
mally considered when looking at cell proliferation and
cancer (PtdIns3P levels are comparable in resting and
growth factor stimulated cells), it cannot be completely
ruled out as inhibitory antibodies specific for hVps34 can
block insulin-stimulated DNA synthesis [13].
Class IV: PI3K-related enzymes
This family of high molecular weight proteins includes the
target of rapamycin (TOR)/FKBP rapamycin-associated
protein and the ataxia telangiectasia mutated/ataxia
telangiectasia related/DNA-dependent protein kinase
(ATM/ATR/DNA-PK) family of enzymes [6,14]. TOR pro-
teins were cloned as targets of rapamycin, a fungicide and
immunosuppressant [14]. They have subsequently been
linked to the integration of mitogenic and nutritional
signals through the regulation of initiation of translation via
the substrates p70 S6 kinase and eukaryotic initiation 4E
binding protein (4E-BP-1 or PHAS-1) and entry into the
G1 phase of the cell cycle [14]. ATM, ATR and DNA-PK
are linked to meiotic and V(D)J recombination, repair and
maintenance of chromosomes (in response to various
damaging agents including ionising radiation), and cell-
cycle checkpoint control [6]. While Class IV enzymes
possess some of the conserved motifs present in the cat-
alytic domain of the true PI3Ks, they lack others such as
the PIK domain (Fig. 1). Although initial studies suggested
that Class IV enzymes might have lipid kinase activity, the
consensus is that they are all exclusively protein kinases.
Class IV enzymes are considered here for two reasons:
they are sensitive to the widely used PI3K inhibitors (see
next section), and they are linked to diverse human dis-
eases ranging from immunological disorders to cancer,
including that of the breast.
PI3K family inhibitors
There are two commonly used, structurally unrelated, cell-
permeable PI3K inhibitors: wortmannin and LY294002
[4,5]. Much of the work linking PI3K activity to various
cellular processes has been carried out using these PI3K
inhibitors, and this has led to many processes being linked
to PI3K activity. However, there is less information as to
which of the classes of enzyme described in the preced-
ing sections are involved in specific processes. These
PI3K inhibitors do not distinguish between the differentBreast Cancer Research    Vol 3 No 5 Fry
PI3K isoforms or Classes I–III and, in addition, when used
at higher concentrations (>100 nM wortmannin, >50 µM
LY294002) they inhibit the Class IV PI3K-related protein
kinases. Both agents have been shown experimentally to
inhibit tumour growth and to sensitise cells to radiation
treatment, and this has enhanced the idea that PI3Ks are
potential therapeutic targets [4,15–18].
PI3K signalling
The molecular basis of PI3K signalling has emerged in the
past few years and is dependent on the presence of lipid
recognition modules found in target proteins. The two key
domains so far identified are the pleckstrin homology (PH)
domain and the FYVE domain [3,5]. The FYVE domain
seems to be involved predominantly in the recognition of
PtdIns3P. PH domains with specificity for PtdIns(3,4,5)P3,
PtdIns(3,4)P2, PtdIns(4,5)P2 and PtdIns3P have been
reported [3,5]. On activation of an appropriate PI3K, 3-
phosphorylated inositol lipids are produced in the target
membrane and proteins containing high-affinity binding
sites for these lipids are subsequently recruited. Key PH
domain proteins involved in signalling via PI3Ks include
the phosphoinositide-dependent protein kinase 1 (PDK1),
protein kinase B (Akt) and a number of exchange factors
for small G proteins of the Ras superfamily [3,5]. Recruit-
ment of these signalling proteins to membranes brings
them into close contact with their substrates or target pro-
teins, thus potentiating further signalling events.
Figure 1
The phosphoinositide 3-kinase (PI3K) superfamily. Schematic representation of the catalytic subunits of the PI3K superfamily of enzymes. The names
of the kinases are given on the left, together with their size (kDa). Classification by class is indicated by the bars on the right. Recognised domains
are indicated. ATM/ATR/DNA-PK, Ataxia telangiectasia mutated/ataxia telangiectasia related/DNA-dependent protein kinase; FAT, domain present in
FKBP rapamycin-associated protein/target of rapamycin (TOR), ATM and TRRAP (ATM-related) proteins; FATC, C-terminal domain found only in FAT
domain containing proteins; FRB, FKBP12/rapamycin binding domain; HEAT, domain found in Huntington, EF3, a subunit of protein phosphatase 2A
and TOR; HR1–HR4, homology region; p85 BD, p85 binding domain; PH, pleckstrin homology; PX, phox homology; RBD, Ras binding domain.Termination of PI3K signalling is caused by the action of
phosphoinositide (PI) phosphatases that work on distinct
phosphates of the inositol ring (Fig. 2). The 5-PI phos-
phatases can attenuate Class I PI3K signalling by remov-
ing the 5′ phosphate of PtdIns(3,4,5)P3. This results in the
production of PtdIns(3,4)P2, whichis also a signalling mol-
ecule and the preferred binding lipid for several PH
domains [3]. PI3K signalling can be completely terminated
by the action of a recently identified family of dual-speci-
ficity protein phosphatases/3-PI phosphatases. The proto-
type member of this family is the tumour suppressor gene
product PTEN, the phosphatase and tensin homologue
deleted on chromosome 10 (also known as MMAC-1 and
TEP-1) [19]. Because this phosphatase acts specifically
on the 3′ phosphate, it has the potential to inactivate all
possible PI3K products.
The best understood PI3K target is Akt, a serine/threo-
nine kinase [20]. Akt is recruited, on PI3K activation and
3-PI production, to cell membranes via its PH domain.
This interaction also appears to expose a phosphorylation
site in the activation loop that is then phosphorylated by
other kinases stimulated by 3-PIs including PDK1 and
PDK2. Once activated, Akt phosphorylates a number of
proteins leading to regulation of metabolism (via glycogen
synthase kinase 3), translational control (via p70 S6
kinase and PHAS-1), and cell survival (via forkhead family
transcription factors, BAD and caspase 9) [20]. Akt is
also linked to regulation of the cell cycle through cyclin
D1 and E2F [20].
PI 3-kinase family signalling in cancer
PI3K activity has, from the start, been linked with many
aspects of the cell transformation process, including
increased cell growth, proliferation and survival, adhe-
sion, metastasis and angiogenesis [2]. The first reports
of PI3K activity saw it linked to transforming gene prod-
ucts of the acutely transforming retroviruses, such as v-
Src and v-Ros, and to polyoma virus mT [1]. It was
subsequently shown that the presence of PI3K activity is
critical for the transforming potential of these onco-
genes. Mutant forms of mT, Src and Abl viral oncopro-
teins, which fail to bind and activate PI3K, are greatly
impaired in transforming ability. This activity is believed
to be a Class I PI3K.
Class I PI3Ks
In 1997, a Class IA PI3K catalytic subunit was isolated as
the transforming gene of a chicken sarcoma virus, v-p3k
[2]. This virus is fused with the retroviral gag gene, result-
ing in a gag-v-p3k fusion protein that is N-terminal myris-
toylated and targeted to cell membranes. Experimental
manipulation of Class I PI3K by the addition of membrane
targeting sequences leads to the formation of constitu-
tively active PI3K that is able to induce many aspects of
cell transformation [2].
The first direct reports that PI3K catalytic subunits might be
altered in human cancer came with the reports that amplifi-
cation of 3q26 is seen in 40% of ovarian cancer and in
many other cancers. The PIK3CA gene (encoding the
Class I p110α) is located at this locus, and ovarian and
cervical tumours were found to have elevated protein and
PI3K activity levels [2,21]. Surprisingly, given the evidence
for the activation of Class IA catalytic subunits in cancer, it
has recently been reported that the loss of the Class IB
enzyme PI3Kγ results in colorectal adenocarcinomas in
mice. It has also been reported that this is also observed in
primary colorectal adenocarcinoma and in colon cancer
cell lines in humans. A possible tumour suppressor role for
some PI3Ks therefore also needs to be considered [2].
There is no strong evidence to date in support of any role
for Class II or III PI3Ks in human cancer, although there
have so far been few studies in this area.
Target of rapamycin
The ability of TOR to act as an oncogene remains to be
determined, but TOR activity is required for PI3K-medi-
ated and Akt-mediated cell transformation [22]. This fits
with experimental data that places TOR downstream of
PI3K/Akt in signalling cascades and points to the impor-
tance of this pathway to aspects of the fully transformed
phenotype. A number of human tumour cell lines have
been reported sensitive to growth inhibition by rapamycin,
thus the TOR proteins may provide a more selective
target for a chemotherapeutic agent. A derivative of
rapamycin with antitumour activity, CCI-779, is currently
in phase I trials [23].
PI3K family in normal and malignant breast
A polymerase chain reaction based screen has been used
to identify PI3Ks in the human breast using mRNA derived
from cells and epithelial tissue from reduction mammo-
plasty. Using this approach, all eight Class I–III PI3K iso-
forms were identified [10]. Of the eight PIKs, all but the
Class IB PI3Kγ were expressed in the epithelial compo-
nent of the tissue. Most PI3Ks are widely expressed in
human tissues, but the PI3K-C2γ isoform is expressed to
significant levels only in the breast, prostate and liver
[10,11]. Detailed studies of PI3K catalytic subunit expres-
sion in breast cancer are rare. However, a recent study on
a series of tumour and adjacent mammary glands from 33
patients observed increased levels of p85 regulatory
subunit in the tumour over adjacent tissues in 79% of their
pairs, which was not linked to other prognostic factors
[24]. Further studies focusing on the catalytic subunits
and lipid products are clearly necessary to assess the rel-
evance of this finding.
Evidence for PI3Ks playing a role in mammary carcinogen-
esis arises primarily from animal model studies and cell-
based studies. Amundadottir and Leder [25] studied five
different transgenic mouse models of malignant transfor-
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heregulin/NDF, TGFα, v-Ha-ras and c-myc) and found, on
the basis of inhibitor studies using LY294002, that PI3K
activity made a contribution to all the transformed pheno-
types (in particular, to anchorage-independent growth).
PI3K is also implicated in transformation of the murine
mammary gland mediated by polyoma virus mT, where
studies with mutants of mT defective in binding PI3K
where shown to induce high levels of apoptosis [26].
Activation of PI3K signalling by PTKs in
breast cancer
The best-studied mechanism of Class I PI3Ks activation is
via their recruitment to activated PTKs [1]. PI3Ks can be
activated via signalling through ErbB family receptors
(mainly via association with ErbB3, which has six PI3K
binding sites). It is therefore likely that, in the many breast
tumours where there is amplification of ErbB family
members, in particular of ErbB2, that there will also be
enhanced PI3K signalling (Fig. 2) [4,27,28]. Activation of
PI3K through either growth factor activation or overexpres-
sion of ErbB family receptors is linked to enhanced migra-
tion of breast cancer cells [29,30]. The cytoplasmic PTK
Src is overexpressed in a high percentage of breast
cancers, and this kinase is capable of sensitising cells to
signalling via EGF. One of the effects of Src overexpres-
sion is to enhance coupling of the EGF receptor to PI3K
signalling [31]. Another cytoplasmic PTK, BRK, has
Breast Cancer Research    Vol 3 No 5 Fry
Figure 2
Phosphoinositide 3-kinase (PI3K) signalling and cancer. Schematic signalling pathway indicating the interactions that occur between known breast
cancer oncogenes (ErbB2, Src) and tumour suppressors (PTEN, BRCA1) with components of the PI3K signalling cassette. Direct physical
interactions are shown with solid arrows. Processes involving several steps are indicated with a dashed arrow; +, an activation step. Blunt arrows
indicate inhibitory effects. Akt, Protein kinase B; ATM, ataxia telangiectasia mutated; ER, oestrogen receptor; 3-Ptase and 5-Ptase,
phosphoinositide 3-phosphatase and phosphoinositide 5-phosphatase activities; PTEN, phosphatase and tensin homolog deleted on chromosome
10; TOR, target of rapamycin.recently been implicated as possibly playing a role in
breast cancer. BRK has a similar domain structure to the
Src family non-receptor PTKs. Whereas BRK expression
is low or undetectable in normal mammary tissue or
benign lesions, 27% of breast tumours overexpress BRK
fivefold or more [32]. Overexpression of BRK in mammary
epithelial cells enhances the ability of the cells to grow in
an anchorage-independent manner and sensitises them to
EGF [33]. BRK overexpression has recently been shown
to enhance the coupling of EGF signalling to PI3K/Akt via
ErbB3 receptor phosphorylation [34]. These effects on
PI3K and Akt activities may account for the ability of BRK
to enhance mammary epithelial cell mitogenesis, and
raises the possibility that breast tumours overexpressing
BRK may have enhanced resistance to apoptotic signals.
Taken together, these facts suggest that overexpression,
or activation, of various PTKs in breast cancer may lead to
PI3K signalling in a high percentage of breast tumours.
This clearly deserves further study.
PTEN, negative regulator of PI3K signalling
Deregulation of PI3K signalling can also arise from the
loss of the normal regulatory proteins. PTEN is clearly a
major regulator of the 3-PIs produced by PI3Ks [19].
PTEN maps to 10q23, a chromosomal region that fre-
quently displays loss of heterozygosity. Mutation of PTEN
is one of the more common somatic mutations in human
cancer and is found particularly in ovarian, prostate and
glioblastoma cancers. Germ-line mutations in the PTEN
gene are responsible for Cowden syndrome, of which
breast cancer is a major feature. Loss of heterozygosity at
the PTEN locus 10q23 is observed in 30–40% of spo-
radic breast cancers, but reports of PTEN mutations
suggest that this occurs only in <5% of breast tumours.
Evidence for a complete lack of PTEN protein in cases
with hemizygous deletions of PTEN, however, suggests
that an epigenetic mechanism may also play a role [35].
Loss of PTEN activity, whether by point mutation or dele-
tion, results in elevated levels of 3-PIs and activation of
PI3K targets such as Akt [2,19]. Studies of PTEN-
deficient mice have found that the loss of this gene alone
only rarely results in mammary carcinomas. However, the
loss of PTEN accelerates the development of mammary
oncogenesis by other mammary oncogenes not known to
target PI3K signalling, such as Wnts [36]. Conversely,
overexpression of PTEN in MCF-7 breast cancer cells
induces apoptosis and cell-cycle arrest through a combi-
nation of PI3K/Akt-dependent and PI3K/Akt-independent
pathways [37].
PI3K, Akt and cyclin D1
There are three Akt proteins (proteins 1–3, i.e. PKBα,
PKBβ and PKBγ) that are widely expressed in most human
tissues [20]. Prior to identification as a PI3K target, Akt
had been found as a retroviral oncogene (gag-akt). Akt
genes are amplified, or the protein is overexpressed, in a
number of human cancers including gastric, ovarian,
breast, pancreatic and prostate cancer [20]. Interestingly,
Akt3 is found to be upregulated in both oestrogen recep-
tor (ER)-deficient breast cancers and in androgen-inde-
pendent prostate cancer cell lines, suggesting this
enzyme may contribute to the more aggressive clinical
phenotype of these diseases [38].
D-type cyclins are targets for a number of growth-factor
signalling pathways and their expression is elevated in a
number of human tumours including those of the breast.
D-type cyclins associate with cyclin-dependent kinases to
form active complexes involved in the regulation of the
retinoblastoma protein, and thus are involved in cell-cycle
regulation. Several lines of evidence suggest that PI3K
signalling is important in the regulation of cyclin D1 at a
post-transcriptional level [39,40]. Coexpression of an acti-
vated form of Akt with a transformation-defective polyoma
virus mT mutant incapable of interacting with PI3K led to
upregulation of cyclin D1 and a dramatic acceleration of
mammary tumourigenesis that correlated with reduced
apoptotic cell death [41]. Activated Akt was unable,
however, to restore wild-type metastasis levels.
BRCA1 and PI3K signalling
Links have also been forged between PI3K superfamily
members, PI3K signalling pathways, and other gene prod-
ucts involved in breast cancer, notably BRCA1. Hereg-
ulins, a group of growth factors that regulate growth,
differentiation and survival of a number of breast cancer
cell lines, bind to members of the ErbB family of receptors
and initiate signalling via Ras/MAPK and PI3K pathways.
Heregulins have been shown to induce phosphorylation of
BRCA1 in breast cancer cells in a PI3K/Akt-dependent
manner [42]. A constitutively active PI3K was sufficient to
induce BRCA1 phosphorylation, which could be blocked
by PI3K inhibitors or by dominant negative Akt expression.
Akt was shown to directly phosphorylate BRCA1 in vitro
at a site close to the nuclear localisation signal sequence.
Several lines of evidence have suggested that BRCA1
phosphorylation during cell-cycle progression and in
response to a DNA damaging agent may affect its func-
tion. While the significance of this phosphorylation is cur-
rently unclear, its site close to the nuclear localisation
sequence suggests that it may affect nuclear translocation
and hence BRCA1 function.
ATM and cancer
Loss of ATM results in the hereditary syndrome ataxia
telangiectasia [6]. Carriers who harbour single germ-line
mutations in ATM are reported to be at increased risk of
breast cancer (see [43] and references therein). This link
between ATM and breast cancer remains controversial,
since ATM mutations have not been found in large breast
cancer case–control studies [44]. It has been hypothe-
sised, however, that this may be owing to the presence of
Available online http://breast-cancer-research.com/content/3/5/304
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emore than one type of ATM heterozygote, and to the
approaches taken to identify ATM mutations in large-scale
studies that have largely focused on looking for truncating
mutations rather than missense types of mutation [45].
Biochemical data also implicates ATM in breast cancer.
BRCA1 is a target for phosphorylation by the Class IV
PI3Ks, ATM and ATR, in response to infrared-induced and
ultraviolet-induced DNA damage, respectively (Fig. 2)
[46–48]. ATM also phosphorylates a BRCA1-associated
protein, CtIP, which may modulate BRCA1-dependent
regulation of the DNA damage response gene GADD45
[49]. Both ATM and ATR kinases are able to phosphory-
late another breast cancer predisposition gene p53, the
cause of Li–Fraumeni syndrome [6]. If one role of ATM/
ATR is to transmit cell cycle or DNA damage signals to
BRCA1 and p53, then this may explain why loss (or partial
loss) of ATM function may lead to an increase in suscepti-
bility to breast cancer.
PI3K signalling and oestrogen-mediated
responses in breast tumour cells
A PIK activity was first reported associated with the ER in
1986 [50]. A recent report suggests that, in vascular
endothelial cells, this interaction involves a Class I PI3K
and a non-nuclear ER [51]. PI3K activity has also been
linked to both proliferative and anti-apoptotic affects of
oestrogen in breast and other tissues [52–54]. Further
complications in this area arise from two recent reports
that PI3K/Akt can activate the ER in the absence of
oestrogen [55,56]. This might help to explain how anti-
oestrogen resistant growth of ER-positive tumours, a sig-
nificant clinical problem, may arise. This is clearly an area
in need of further research.
Conclusions
PI3K activity is associated with a broad range of cancer-
related functions, including cell proliferation, survival, and
migration, that has resulted in increased interest in the
PI3K family as drug targets [4]. Given the number of
tumours in which a component of the PTK/PI3K/PTEN/Akt
cassette is altered (Fig. 2), it is probable that this pathway
will make a significant contribution to a high percentage of
cancers, which at present can only be guessed at. What is
also clear is that this pathway, and those regulated by the
Class IV PI3K-related enzymes such as ATM, can also
interact with BRCA1 and p53, suggesting that all these
proteins may be functionally linked in the maintenance of
normal breast tissue status. What percentage of breast
cancers might have activated PI3K signalling is not clear.
However, given that PI3Ks are activated by ErbB family
PTK receptors as well as by the cytoplasmic PTKs Src
and BRK (which together are overexpressed in >25% of
all breast tumours), and given that Ras mutations and
PTEN loss are each found in another ~5% of breast
tumours, it may be that a significant number of breast
tumours would be targets for small molecules directed at
components of PI3K signalling.
How can this be clarified? There is currently no suitable
test for looking at changes of 3-PIs in clinical samples and
sections. Various PH and FYVE domain reporters coupled
to detection systems, currently in use to study changes in
lipid levels and location in cell-based assays, may soon
provide the tools to look at these changes. At present, the
best indication of PI3K activation (by any means), or PTEN
loss, is probably to screen tumours with antibodies that
recognise the phosphorylated (active) form of Akt.
Do more specific PI3K inhibitors have potential as useful
inhibitors of breast tumour growth or as sensitising
agents for use with radiotherapy? Given the widespread
commercial interest in these drugs, it is hoped that
second-generation PI3K inhibitors should start to see the
light of day in phase I trials and in research laboratories in
the next few years [4]. Preliminary studies have shown
that, at high concentrations (high nanomolar–low micro-
molar), even the low specificity PI3K inhibitors, such as
wortmannin, have in vitro and in vivo anti-tumour activity
against a variety of tumours including mammary tumours
[15,18]. While demonstrating the potential of wortmannin
as a chemotherapeutic agent, these effects do not corre-
late well with inhibition of PI3K activity and thus may be
owing to the inhibition of other PI3K-related enzymes
such as TOR or ATM/ATR/DNA-PK [18]. Possible uses
of PI3K inhibitors can be envisaged when administered
as part of a combinatorial therapy with other agents.
Wortmannin has been shown to have a number of poten-
tial effects on tumours, including sensitising them to the
effects of radiation [16] and enhancing the toxicity of
receptor-directed-toxin chimeras [17]. What is needed
now is some way of specifically delivering them to the
tumour. There appears to be a lot of potential here and
further work is clearly needed to fully assess the contribu-
tion that the PI3Ks and their signalling cassettes play in
the development of breast disease.
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